Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

China's Adagene Inc, a Nasdaq-listed innovative biopharmaceutical company focusing on discovery and development of antibody-based novel cancer immunotherapy, announced collaboration and inked an ...

A visitor looks at the introduction of medicines for vaccines and chronic diseases at the Sanofi booth at the 5th CIIE in Shanghai on Nov 7, 2022. [Photo/VCG] French pharmaceutical company Sanofi will ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.

Adagene Inc. (NASDAQ:ADAG) saw its shares rise by 6.1% on Tuesday after the biotech firm revealed a strategic investment deal ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as ...

Adagene's lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.

Adagene has a 52 week low of $1.33 and a 52 week high of $3.58. The company’s 50-day simple moving average is $1.84 and its 200 day simple moving average is $2.12. Institutional Trading of Adagene ...